Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
Resources, news and special offers to support you and your professional development during this difficult time.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
Download your copy of the new events calendar and see all the online workshops, conferences, RAC exams and European online workshops RAPS has planned for 2021 at a glance.
Registration is now open for RAPS Euro Convergence 2021! Attend to join peers from EU and around the world to gain insights and exchange ideas on the regions most pressing issues.
An invaluable resource for any professional engaged in designing, composing, compiling, or commenting on regulatory documentation
From self-assessments to help you identify your strengths and areas to focus on to reference books and online courses that will help you fill in the gaps in your regulatory knowledge, RAPS has the resources to help you prepare for the RAC exam.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
Posted 10 August 2012 | By Louise Zornoza,
The Citizens Council of the UK's National Institute for Health and Clinical Excellence (NICE), which provides public input into the Institute's work, has published its final report on a November 2011 meeting on the issue of how NICE should assess future costs and health benefits.
The Council members' views on the issue of discounting -the way in which health benefits are valued and calculated over a very long period of time-will be used to guide the methods used by NICE's independent advisory committees. Discounting, a familiar concept in the retail sector, presents a particular challenge in healthcare since it usually involves upfront costs in return for the promise of future benefits.
As people tend to prefer benefits 'now', discounting usually places a lower value on benefits that occur a long way in the future than those occurring immediately. To determine the value of the benefit in the future compared to now, the value is adjusted by a certain amount which is called the discount rate.
NICE's central function is to assess whether clinical and public health interventions are value for money, and discounting presents particular issues for the Institute's advisory committees. "Different views on valuing future health benefits and costs translate into different discount rates, and … this affects conclusions on whether a new treatment could be considered cost effective or not," said NICE Chair Sir Michael Rawlins in a statement.
Rawlins added that, "The Citizens Council's view is that discounting is a valid aspect of the calculation of future costs and benefits. The Council also considered instances where the costs are upfront and the benefits accrue over a long period of time. In such cases the Council advised the Institute that it should depart from its current discounting policy-which is in line with all public bodies-of applying a 3.5% discount rate for costs and benefits."
Rawlins noted the Citizens Council hopes, "That NICE would take appropriate action should any occasions of public health being disadvantaged arise."
Such a scenario has, in an unrelated case, recently arisen. In early August Rawlins called on the National Health Service (NHS) to clamp down on local trusts restricting access to NICE-approved medications, saying the trusts were "denying patients an innovative and cost-effective treatment…that significantly improves their quality of life."
Read more:
NICE - Citizens Council report: discounting
Read all Breaking News from RegLink
Tags: Discounting, benefits
Regulatory Focus newsletters
All the biggest regulatory news and happenings.